Mdm2 targeting via PROteolysis TArgeting Chimeras (PROTAC) is efficient in p53 wildtype, p53-mutated, and abemaciclib-resistant estrogen receptor-positive cell lines and superior to mdm2 inhibition.

IF 3.4 2区医学 Q2 ONCOLOGY

BMC Cancer Pub Date : 2025-06-01 DOI:10.1186/s12885-025-14361-z

Alina Goerg, Gerhard Piendl, Veruschka Albert, Olaf Ortmann, Anja Kathrin Wege, Gero Brockhoff

引用次数: 0

查看原文本刊更多论文

通过蛋白水解靶向嵌合体（PROteolysis targeting Chimeras， PROTAC）靶向Mdm2在p53野生型、p53突变型和abemaciclib抗性雌激素受体阳性细胞系中有效，优于Mdm2抑制。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

BMC Cancer 医学-肿瘤学

CiteScore

6.00

自引率

2.60%

发文量

1204

审稿时长

6.8 months

期刊介绍： BMC Cancer is an open access, peer-reviewed journal that considers articles on all aspects of cancer research, including the pathophysiology, prevention, diagnosis and treatment of cancers. The journal welcomes submissions concerning molecular and cellular biology, genetics, epidemiology, and clinical trials.